Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
企業コードIXHL
会社名Incannex Healthcare Inc
上場日Mar 18, 2022
最高経営責任者「CEO」Latham (Joel)
従業員数12
証券種類Ordinary Share
決算期末Mar 18
本社所在地8 Century Circuit
都市
証券取引所NASDAQ OMX - NASDAQ BASIC
国Australia
郵便番号2153
電話番号61409840786
ウェブサイト
企業コードIXHL
上場日Mar 18, 2022
最高経営責任者「CEO」Latham (Joel)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし